ImCheck Therapeutics aims to broaden the reach of cancer immunotherapy with antibody drugs that activate a rare but powerful type of immune cell called gamma delta T cells. The biotech has unveiled €96 million to advance its pipeline, including a lead candidate in development for both liquid and solid tumors.
